Preferred Label : Lenvatinib/Pembrolizumab Regimen;
NCIt synonyms : Pembrolizumab/Lenvatinib Regimen; Pembrolizumab-Lenvatinib; Lenvatinib-Pembrolizumab; Lenvatinib/Pembrolizumab; Keytruda/Lenvima; Pembrolizumab/Lenvatinib;
NCIt related terms : Lenvatinib and Pembrolizumab;
NCIt definition : A regimen consisting of lenvatinib and pembrolizumab that may be used for the treatment
of cutaneous melanoma, hepatobiliary cancers, advanced endometrial carcinoma and advanced
renal cell carcinoma (RCC).;
NCI Metathesaurus CUI : CL1663648;
Codes from synonyms : 48278;
Origin ID : C180910;
UMLS CUI : C5556711;
Est indiqué pour
- Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3498750/fr/keytruda-pembrolizumab-carcinome-a-cellules-renales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
clear cell renal cell carcinoma
Lenvatinib/Pembrolizumab Regimen
Advanced Clear Cell Renal Cell Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
pembrolizumab
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell
---
https://www.has-sante.fr/jcms/p_3325606/fr/lenvima-lenvatinib
https://www.has-sante.fr/jcms/p_3325613/fr/decision-n-2022-0080/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-lenvima
https://www.has-sante.fr/jcms/p_3328914/fr/decision-n-2022-0107/dc/sem-du-31-mars-2022-du-college-de-la-haute-autorite-de-sante-modifiant-la-decision-n-2022-0080/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-lenvima
2022
false
false
false
France
Lenvatinib/Pembrolizumab Regimen
antineoplastic combined chemotherapy protocols
pembrolizumab
insurance, health, reimbursement
treatment outcome
endometrial neoplasms
Advanced Endometrial Carcinoma
neoplasm metastasis
neoplasm recurrence, local
Recurrent Endometrial Carcinoma
administration, oral
lenvatinib
protein kinase inhibitors
antineoplastic agents
evaluation of the transparency committee
lenvatinib
---
https://www.has-sante.fr/jcms/p_3334585/fr/keytruda-pembrolizumab-cancer-de-l-endometre
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
infusions, intravenous
pembrolizumab
Antineoplastic Agents, Immunological
adult
Lenvatinib/Pembrolizumab Regimen
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
neoplasm recurrence, local
neoplasm metastasis
economic evaluation
evaluation of the transparency committee
endometrial neoplasms
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3321831/fr/kisplyx-lenvatinib-cancer-du-rein-uniquement-a-cellules-claires
2022
false
false
false
France
lenvatinib
protein kinase inhibitors
antineoplastic agents
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
pembrolizumab
clear cell renal cell carcinoma
Lenvatinib/Pembrolizumab Regimen
Advanced Clear Cell Renal Cell Carcinoma
administration, oral
Product containing precisely lenvatinib (as lenvatinib mesilate) 10 milligram/1 each
conventional release oral capsule (clinical drug)
Product containing precisely lenvatinib (as lenvatinib mesilate) 4 milligram/1 each
conventional release oral capsule (clinical drug)
evaluation of the transparency committee
lenvatinib
---
https://www.has-sante.fr/jcms/p_3324073/fr/kisplyx-lenvatinib
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
lenvatinib
administration, oral
lenvatinib
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
Lenvatinib/Pembrolizumab Regimen
pembrolizumab
clear cell renal cell carcinoma
Advanced Clear Cell Renal Cell Carcinoma
evaluation of the transparency committee
lenvatinib
---
